Usefulness of contrast-enhanced intraoperative ultrasound in identifying disappearing liver metastases from colorectal carcinoma after chemotherapy

Annals of Surgical Oncology

Volumn 21, Issue SUPPL. 3, 2014, Pages

  Arita, Junichi ^a   Ono, Yoshihiro ^a   Takahashi, Michiro ^a   Inoue, Yosuke ^a   Takahashi, Yu ^a   Saiura, Akio ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CETUXIMAB; GADOXETIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; PERFLUBUTANE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CONTRAST MEDIUM; GADOLINIUM PENTETATE; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ASSESSMENT; COLORECTAL CARCINOMA; COLORECTAL LIVER METASTASIS; COMPUTER ASSISTED TOMOGRAPHY; DISAPPEARING LIVER METASTASIS; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEROPERATIVE ECHOGRAPHY; PREOPERATIVE PERIOD; RETROSPECTIVE STUDY; SENSITIVITY ANALYSIS; SUSCEPTIBILITY WEIGHTED IMAGING; TUMOR GROWTH; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; CANCER STAGING; CONTRAST ENHANCED INTRAOPERATIVE ULTRASOUND; CONTRAST ENHANCEMENT; LIVER INJURY; LIVER METASTASIS; LIVER RESECTION; LUNG METASTASIS; LYMPH NODE METASTASIS; PREOPERATIVE CARE; VERY ELDERLY; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; DIAGNOSTIC USE; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; LIVER NEOPLASMS; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; NEOPLASM, RESIDUAL; PATHOLOGY; PEROPERATIVE CARE; PROGNOSIS; SECONDARY; SURVIVAL RATE; UTILIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; CONTRAST MEDIA; FEMALE; FOLLOW-UP STUDIES; GADOLINIUM DTPA; HEPATECTOMY; HUMANS; INTRAOPERATIVE CARE; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASM, RESIDUAL; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 84903310621     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-014-3576-y     Document Type: Article

References (30)

1. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240(4):644-657; discussion 657-648.
2. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008;371(9617):1007-1016. (Pubitemid 351392040)
3. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA. Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg. 2010;14(11):1691-1700.
4. Diane G, Sebastien G, Frederic D, et al. Patients operated on for initially unresectable colorectal liver metastases with missing metastases have a favorable long-term outcome. Ann Surg. 2011;254(1):114-118.
5. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure? J Clin Oncol. 2006;24(24):3939-3945. (Pubitemid 46630742)
6. Tanaka K, Takakura H, Takeda K, Matsuo K, Nagano Y, Endo I. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg. 2009;250(6):935-942.
7. Auer RC, White RR, Kemeny NE, et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010;116(6):1502-1509.
8. Torzilli G, Del Fabbro D, Palmisano A, et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg. 2005;9(8):1148-1153.
9. Leen E, Ceccotti P, Moug SJ, et al. Potential value of contrast-enhanced intraoperative ultrasonography during partial hepatectomy for metastases: an essential investigation before resection? Ann Surg. 2006;243(2):236-240. (Pubitemid 43185443)
10. Takahashi M, Hasegawa K, Arita J, et al. Contrast-enhanced intraoperative ultrasonography using perfluorobutane microbubbles for the enumeration of colorectal liver metastases. Br J Surg. 2012;99(9):1271-1277.
11. Kindberg GM, Tolleshaug H, Roos N, Skotland T. Hepatic clearance of sonazoid perfluorobutane microbubbles by Kupffer cells does not reduce the ability of liver to phagocytose or degrade albumin microspheres. Cell Tissue Res. 2003;312(1):49-54. (Pubitemid 36578845)
12. Watanabe R, Matsumura M, Munemasa T, Fujimaki M, Suematsu M. Mechanism of hepatic parenchyma-specific contrast of microbubble-based contrast agent for ultrasonography: microscopic studies in rat liver. Invest Radiol. 2007;42(9):643-651. (Pubitemid 47262933)
13. Yanagisawa K, Moriyasu F, Miyahara T, Yuki M, Iijima H. Phagocytosis of ultrasound contrast agent microbubbles by Kupffer cells. Ultrasound Med Biol. 2007;33(2):318-325. (Pubitemid 46240604)
14. Conlon R, Jacobs M, Dasgupta D, Lodge JP. The value of intraoperative ultrasound during hepatic resection compared with improved preoperative magnetic resonance imaging. Eur J Ultrasound 2003;16(3):211-216. (Pubitemid 36173577)
15. Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology 2011;260(2):446-453.
16. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-1321. (Pubitemid 40770284)
17. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 2005;200(6):845-853. (Pubitemid 40744790)
18. Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15(3):460-466. (Pubitemid 38444550)
19. Lubezky N, Metser U, Geva R, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11(4):472-478.
20. Angliviel B, Benoist S, Penna C, et al. Impact of chemotherapy on the accuracy of computed tomography scan for the evaluation of colorectal liver metastases. Ann Surg Oncol. 2009;16(5):1247-1253.
21. Elias D, Goere D, Boige V, et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol . 2007;14(11):3188-3194. (Pubitemid 47594272)
22. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer 2007;110(12):2761-2767. (Pubitemid 350250347)
23. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: myth or reality? J Clin Oncol. 2008;26(10):1635-1641.
24. Oudkerk M, Torres CG, Song B, et al. Characterization of liver lesions with mangafodipir trisodium-enhanced MR imaging: multicenter study comparing MR and dual-phase spiral CT. Radiology 2002;223(2):517-524. (Pubitemid 34454337)
25. Kulemann V, Schima W, Tamandl D, et al. Preoperative detection of colorectal liver metastases in fatty liver: MDCT or MRI? Eur J Radiol. 2011;79(2):e1-e6.
26. Eiber M, Fingerle AA, Brugel M, Gaa J, Rummeny EJ, Holzapfel K. Detection and classification of focal liver lesions in patients with colorectal cancer: retrospective comparison of diffusion-weighted MR imaging and multi-slice CT. Eur J Radiol. 2012;81(4):683-91.
27. Muhi A, Ichikawa T, Motosugi U, et al. Diagnosis of colorectal hepatic metastases: comparison of contrast-enhanced CT, contrast-enhanced US, superparamagnetic iron oxide-enhanced MRI, and gadoxetic acid-enhanced MRI. J Magn Reson Imaging 2011;34(2):326-335.
28. Sugimoto K, Shiraishi J, Moriyasu F, Saito K, Doi K. Improved detection of hepatic metastases with contrast-enhanced low mechanical-index pulse inversion ultrasonography during the liver-specific phase of sonazoid: observer performance study with JAFROC analysis. Acad Radiol. 2009;16(7):798-809.
29. Correas JM, Low G, Needleman L, et al. Contrast enhanced ultrasound in the detection of liver metastases: a prospectivemulti-centre dose testing study using a perfluorobutane microbubble contrast agent (NC100100). Eur Radiol. 2011;21(8):1739-46.
30. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol. 2008;19(3):508-515. (Pubitemid 351325672)